Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31139534 | 1.00 | CSNK2A2 (0.40) | CSNK2A2CSNK2A1MEN1KMT2ACSNK2B | |
| SCHEMBL10285464 | 0.74 | PI4KA (0.34) | CSNK2A2CSNK2A1MEN1KMT2ACSNK2B | |
| Adenine SCHEMBL3413247 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3416954 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3414603 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL8110 | 0.74 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL5720577 | 0.74 | MEN1 (0.33) | CSNK2A2CSNK2A1MEN1KMT2ACSNK2B | |
| SCHEMBL8083818 | 0.74 | MEN1 (0.33) | CSNK2A2CSNK2A1MEN1KMT2ACSNK2B | |
| SCHEMBL11491985 | 0.73 | KDM4E (0.35) | CSNK2A2CSNK2A1MEN1KMT2ACSNK2B | |
| Adenine SCHEMBL7204509 | 0.73 | PI4KA (0.50) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943494-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2022-01-26 | — | — | EP | claimed |
| US-10870650-B2 | Process for the preparation of amorphous idelalisib | NATCO PHARMA LIMITED (IN) | 2020-12-22 | — | — | US | claimed |
| US-20200095249-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB | NATCO PHARMA LIMITED (IN) | 2020-03-26 | — | — | US | claimed |
| WO-2018198131-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB | NATCO PHARMA LIMITED (IN) | 2018-11-01 | — | — | WO | claimed |
| US-20160075705-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2016-03-17 | — | — | US | claimed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-4554944-A2 | KINASE INHIBITORS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2024020333-A2 | KINASE INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| CN-113717240-B | Nucleoside compound and preparation method thereof | 哈尔滨商业大学 | 2023-10-17 | — | — | CN | disclosed |
| WO-2001072294-A2 | METHOD OF TREATING HEPATITIS DELTA VIRAL INFECTION | GEORGETOWN UNIVERSITY (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1104436-A2 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B VIRUS | Idenix (Cayman) Limited (KY) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009531-A2 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-02-24 | — | — | WO | disclosed |
| EP-0544668-A1 | -6-FLUORO-9-(2,3-DIDEOXY-B-D-GLYCERO-PENTOFURANOSYL)-9H-PURINES AND THEIR USE ASANTIVIRAL AGENTS | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1993-06-09 | — | — | EP | disclosed |
| EP-0544668-A4 | 6-HALO- AND 2-AMINO-6-HALO-PURINE 2',3'-DIDEOXY NUCLEOSIDES AND THEIR USE AS ANTIVIRAL AGENTS. | US SECRETARY UNITED STATES DEP (JP) | 1993-03-03 | — | — | EP | disclosed |
| WO-1991012260-A1 | 6-HALO- AND 2-AMINO-6-HALO-PURINE 2',3'-DIDEOXY NUCLEOSIDES AND THEIR USE AS ANTIVIRAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095249-A1 | PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB | IDE, PDE8B, PCSK9 | CSNK2A2 1826/4885CSNK2A1 1891/4885MEN1 1704/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CSNK2A2 78/4885CSNK2A1 67/4885MEN1 4673/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | CSNK2A2 328/4885CSNK2A1 343/4885MEN1 883/4885 |
| US-10870650-B2 | Process for the preparation of amorphous idelalisib | IDE, PDE8B, PCSK9 | CSNK2A2 1826/4885CSNK2A1 1891/4885MEN1 1704/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | CSNK2A2 45/4885CSNK2A1 30/4885MEN1 3578/4885 |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | CSNK2A2 242/4885CSNK2A1 225/4885MEN1 4274/4885 |
| US-20160075705-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | CSNK2A2 242/4885CSNK2A1 225/4885MEN1 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.